Author Archives: Colby Howard

David Little’s macro expertise at DXP Enterprises (DXPE) is notable, but integration and execution challenges may impact his fit with DXPE’s growth goals. Continue reading →

Subodh Kulkarni’s technical expertise at Rigetti Computing (RGTI) may support innovation, but questions remain on his fit amid cash burn and revenue declines. Continue reading →

Sudhir Srivastava’s vision may position SSII for growth, but royalty conflicts and regulatory hurdles could challenge his fit and long-term profitability focus. Continue reading →

Shalabh Gupta’s leadership at Unicycive Therapeutics (UNCY) may not fully align with urgent commercialization needs, raising key questions for investors. Continue reading →

Alan Baratz’s record at D-Wave Quantum (QBTS) suggests his strategic vision may not fully align with QBTS’s urgent need for disciplined cash management. Continue reading →

Ellen Gordon’s operational strengths at Tootsie Roll (TR) may not fully align with urgent needs for market share defense and strategic renewal, analysis finds. Continue reading →

Terry Rosen’s financial discipline at Arcus Biosciences (RCUS) may be offset by past late-stage clinical setbacks, raising key questions about his strategic fit. Continue reading →

Adam Aron’s marketing skills at AMC (AMC) may not fully align with the company’s urgent need for financial discipline and sustainable debt reduction. Continue reading →

Anthony Koblinski’s strategic vision at KRMN has driven backlog growth, but his execution and communication may be less aligned with current DoD client needs. Continue reading →

Mike Bieber’s growth focus at Willdan Group (WLDN) highlights strong contract wins, but questions remain about risk controls and sustained profitability fit. Continue reading →